Study Evaluating AMG 424 in Subjects With Multiple Myeloma

Relapsed/ Refractory Multiple Myeloma Clinical Trial

Official title:
A Phase 1, First-in-Human, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 424 in Subjects With Multiple Myeloma

Status Terminated

Clinical Trial Summary

A multi-center Phase 1, First-in-Human study conducted in 2 Parts, testing AMG 424 in subjects with relapsed/ refractory multiple myeloma.

Clinical Trial Description

Part 1 of the study is dose evaluating and aimed at assessing the safety and tolerability of AMG 424 while determining the maximum tolerated dose (MTD) and/or biologically active dose in subjects with relapsed/ refractory multiple myeloma. Part 2 of the study will further evaluate safety and tolerability of the AMG 424 MTD dose determined in Part 1, in groups of subjects with relapsed/ refractory multiple myeloma that include those with high or low cytogenetic risk. ;

Study Design

Related Conditions & MeSH terms

Multiple Myeloma
Neoplasms, Plasma Cell
Relapsed/ Refractory Multiple Myeloma

Clinical Trial Details

NCT number	NCT03445663
Study type	Interventional
Source	Xencor, Inc.
Contact
Status	Terminated
Phase	Phase 1
Start date	July 31, 2018
Completion date	June 19, 2020

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT05461209` - A Study of Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma	Phase 3
Recruiting	`NCT05338775` - A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma	Phase 1
Recruiting	`NCT05850234` - A Study of GC012F, a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma	Phase 1/Phase 2